Triple antithrombotic therapy in cardiac patients: more questions than answers

Martin Moser1, Christoph B Olivier, Christoph Bode

  • 1Heart Center, Cardiology and Angiology I, Freiburg University, Hugstetter Strasse 55, Freiburg 79106, Germany.

European Heart Journal
|December 5, 2013
PubMed

Insights

Managing cardiac patients on combined antithrombotic therapy, including anticoagulants and anti-platelet drugs, poses bleeding risks. This review explores strategies to minimize bleeding while preventing ischemic events in conditions like atrial fibrillation and acute coronary syndrome.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Many cardiac patients need combined antithrombotic therapy (anticoagulant and anti-platelet inhibition).
  • Common indications include atrial fibrillation (AF) with drug-eluting stents or acute coronary syndrome (ACS).
  • Standard dosing regimens increase bleeding rates.

Purpose of the Study:

  • To review current literature on combined antithrombotic therapy.
  • To discuss approaches for reducing bleeding risk.
  • To maintain efficacy in preventing ischemic events.

Main Methods:

  • Literature review of existing studies on antithrombotic therapy.
  • Analysis of bleeding and ischemic event rates.
  • Evaluation of risk-reduction strategies.

Main Results:

  • Combined antithrombotic therapy is frequently indicated but associated with high bleeding rates.
  • Optimal drug combinations and dosages remain undetermined.
  • Strategies to mitigate bleeding risk are under investigation.

Conclusions:

  • Balancing bleeding and ischemic risks is crucial in combined antithrombotic therapy.
  • Further research is needed to establish optimal treatment protocols.
  • Minimizing bleeding complications without compromising efficacy is a key therapeutic goal.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655